Much-Needed Clarification and Guidance on Cell-Based Therapies for Musculoskeletal Disorders - Secondary Publication.
Much-Needed Clarification and Guidance on Cell-Based Therapies for Musculoskeletal Disorders - Secondary Publication.
复制标题
肌肉骨骼疾病细胞疗法急需的澄清和指导 - 二次出版物。
DOI：
10.1002/jor.24486
复制
发表时间：
2020
期刊：
影响因子：
--
通讯作者：
Longaker,MichaelT
中科院分区：
文献类型：
--
作者：
Murphy,MatthewP;Wan,DerrickC;Longaker,MichaelT
Within the last 30 years, there have been many advancements within the field of stem cell biology, and controversies regarding their clinical implementation make the joint American Society for Bone and Mineral Research (ASBMR) and the Orthopaedic Research Society (ORS) Task Force by O’Keefe and colleagues especially timely. 1 Early descriptions of “the mesenchymal stem cell” by Friedenstein2 and colleagues and later by Caplan3 characterized these progenitors as a nonhematopoietic cell expanded by in vitro culture with t he ability to self-renew and differentiate along multiple lineages. Since then, our understanding and ability to isolate pure populations of tissue-resident stem cells has allowed for the more accurate determination of key cellular signaling pathways. 4, 5 The ability to induce pluripotency creating induced pluripotent stem cells (iPSCs) has further opened the door for use of progenitor cells in disease modeling, drug discovery, and regenerative strategies. 6 Finally, postnatal tissues such as bone marrow, periosteum, fat, brain, skin, and umbilical cord blood have been shown to harbor tissue resident progenitor cells, such as the skeletal stem cell, 5 with significant promise for potential clinical application. 7The present report broaches five main subjects: 1) limitations of cell-based therapies according to their cellular source (encompassing iPSCs, embryonic stem cells [ESCs], bone marrow stromal cells [BMSCs], skeletal stem cells [SSCs], nonskeletal-derived mesenchymal stem cells [MSCs], and differentiated skeletal cells); 2) utility of cell-derived products based on cellular source (encompassing platelet-rich plasma [PRP], conditioned medium, and extracellular vesicles [EV]); 3) tissue-specific animal models of cell-based
